About

What we do

Our services center on the following, either as separate or integrated and bundled projects.

  • scientific strategy in late-stage development and post-approval research of human therapeutics
  • design, management, analysis, and dissemination of clinical real-world studies
  • value assessment and economic analysis
  • equity in access to therapeutics and care
  • litigation support, expert review, and expert opinion
  • evidence synthesis
  • scientific communication
  • scientific due diligence
  • virtual health economics and outcomes research services
  • education and training

We scale our work: molecules to models (m2M) – patients to populations (p2P) – empirics to economics (e2E)

For whom

Our clients are pharmaceutical and biotechnology companies, medical device and diagnostics companies, financial organizations, governments and international agencies, health care providers, and academic institutions – with current and past sponsors in the Americas, Europe, Asia, Oceania, and North-Africa.

What we are (not)

We are experts at what we do. We do not do things we are not experts in. We only take on assignments within our range of competency and capability.

We’re small and we intend to stay that way. We do not aim for an exit, nor do we have an exit horizon.

Our emphasis is on innovation and impact, not on growth and volume. We take on what we can with our core resources and with our extensive network of analytical, technical, and clinical experts in North America, Europe, and Asia.

We’re hard on ourselves. Cliché as it may sound, we want to exceed client expectations (we’re sure you have heard this before). Our clients may be satisfied if we deliver what was contracted. We are glad when we do so – but not satisfied. We aim for more.

We’re affordable – in good part because our overhead and marketing expenses are low and our repeat and follow-on engagement rates are high.

We’re transparent and ethical.

We give back in volunteer and pro bono services.

We have a transition and continuity plan in case life interferes.

Our core analysts have doctorates.

Principals

Ivo Abraham, PhD

Co-Founding Principal and Chief Scientist

Ivo Abraham, PhD (University of Michigan, 1984), is Co-Founding Principal and Chief Scientist. He also serves as Professor of Pharmacy, Medicine, and Clinical Translational Sciences at the University of Arizona, where he is affiliated with the Center for Health Outcomes and PharmacoEconomic Research and the Arizona Cancer Center. He has served on the faculty of Case Western Reserve University (Cleveland, OH), University of Virginia (Charlottesville, VA), and (part-time) KU Leuven (Leuven, Belgium); and as visiting professor at Universiteit Maastricht (Maastricht, The Netherlands), University of Florida (Gainesville, FL), Rijksuniversiteit Groningen (Groningen, The Netherlands), New York University (New York, NY), University of Pennsylvania (Philadelphia, PA), Chang Gung University (Taiwan), and Hyogo University (Japan). He brings 40+ years of expertise at the interface of research, clinical care, economics, and policy worldwide. A native of Belgium, he has served as an expert advisor to the European Union FP and HORIZON health care research programs, including the Innovative Medicines and Innovative Health Initiatives Joint EU/EFPIA Undertaking. He has advised research, health, academic, government, payer, and international organizations in the Americas, Europe, Asia, Oceania, and the Middle East / North Africa since 1985. Prior to co-founding Matrix45, he launched two predecessor companies with narrower but, in part, analogous service lines. He is the Quantitative Methods Editor of JAMA Dermatology and Editor in Chief of the Journal of Medical Economics.

Karen MacDonald, PhD

Co-Founding Principal and Managing Director

Karen MacDonald, PhD (University of Virginia, 2003) is Co-Founding Principal and Managing Director. She has 35+ years of experience in clinical practice and research. Her background in various clinical settings, from intensive care to public health, provides a foundation for understanding the strategic and operational underpinnings of clinical and economic evaluations. She oversees the company’s operations, manages project teams, and actively participates in client engagements.

We have an international network of scientific, technical, and clinical experts supporting our client engagements.